Revusiran
- Generic Name
- Revusiran
- Drug Type
- Biotech
- CAS Number
- 1438322-82-7
- Unique Ingredient Identifier
- ZE6EHM8Z3A
Overview
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
Background
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath